Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 21-27 of 27 (Search time: 0.003 seconds).
previous
1
2
3
next
Item hits:
Preview
Issue Date
Title
Author(s)
2007
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
White, D.
;
Saunders, V.
;
Dang, P.
;
Engler, J.
;
Venables, A.
;
Zrim, S.
;
Zannettino, A.
;
Lynch, K.
;
Manley, P.
;
Hughes, T.
2013
Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: Evidence for site-specific skeletal effects
Vandyke, K.
;
Fitter, S.
;
Drew, J.
;
Fukumoto, S.
;
Schultz, C.
;
Sims, N.
;
Yeung, D.
;
Hughes, T.
;
Zannettino, A.
2003
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
Branford, S.
;
Rudzki, Z.
;
Walsh, S.
;
Parkinson, I.
;
Grigg, A.
;
Szer, J.
;
Taylor, K.
;
Hermann, R.
;
Seymour, J.
;
Arthur, C.
;
Joske, D.
;
Lynch, K.
;
Hughes, T.
2010
Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
Cortes, A.
;
Baccarani, M.
;
Guilhot, F.
;
Druker, B.
;
Branford, S.
;
Kim, D.
;
Pane, F.
;
Pasquini, R.
;
Goldberg, S.
;
Kalaycio, M.
;
Moiraghi, B.
;
Rowe, J.
;
Tothova, E.
;
de Souza, C.
;
Rudoltz, M.
;
Yu, R.
;
Krahnke, T.
;
Kantarjian, H.
;
Radich, J.
;
Hughes, T.
2011
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia
Esposito, N.
;
Colavita, I.
;
Quintarelli, C.
;
Sica, A.
;
Peluso, A.
;
Luciano, L.
;
Picardi, M.
;
Vecchio, L.
;
Buonomo, T.
;
Hughes, T.
;
White, D.
;
Radich, J.
;
Russo, D.
;
Branford, S.
;
Saglio, G.
;
Vaz de Melo, J.
;
Martinelli, R.
;
Ruoppolo, M.
;
Kalebic, T.
;
Martinelli, G.
;
et al.
2018
Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression
McClure, B.
;
Heatley, S.
;
Kok, C.
;
Sadras, T.
;
An, J.
;
Hughes, T.
;
Lock, R.
;
Yeung, D.
;
Sutton, R.
;
White, D.
2017
CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors
Hughes, A.
;
Clarson, J.
;
Tang, C.
;
Vidovic, L.
;
White, D.
;
Hughes, T.
;
Yong, A.
Discover
Author
10
Branford, S.
10
White, D.
8
Hochhaus, A.
8
Radich, J.
7
Grigg, A.
7
Kim, D.
6
Larson, R.
6
Saglio, G.
5
Baccarani, M.
4
Arthur, C.
.
next >
Subject
27
Humans
24
Female
24
Male
23
Middle Aged
20
Aged
20
Pyrimidines
19
Imatinib Mesylate
18
Benzamides
18
Piperazines
17
Leukemia, Myelogenous, Chronic, B...
.
next >
Date issued
12
2010 - 2018
14
2000 - 2009
1
1997 - 1999